Arrowhead Pharmaceuticals (ARWR) FY2021 results: revenue $138 million, up 57.2% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $138 million for fiscal 2021, the year ended 30 September 2021, up 57.2% on the year before. Net income was -$141 million, and diluted earnings per share $-1.36. The figures are the company's own, from the 10-K it filed with the SEC on 22 November 2021.
Revenue
$138 million
+57.2% on the year
FY2014FY2021
Operating margin
-107.8%
-105.9% a year earlier
FY2014FY2021
Net income
-$141 million
FY2014FY2021
Diluted EPS
-$1.36
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Revenue
138
88.0
169
+57.2%
Research and development
206
129
81.0
+60.1%
Operating income
-149
-93.2
61.2
Operating margin
-107.8%
-105.9%
36.3%
Interest expense
0.0
n/a
n/a
Pre-tax income
-141
-84.6
68.1
Income tax
0.0
0.0
0.2
0.0%
Effective tax rate
n/a
n/a
0.3%
Net income
-141
-84.6
68.0
Net margin
-101.9%
-96.1%
40.3%
Diluted EPS
-$1.36
-$0.84
$0.69
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
171
-95.8
173
Capital expenditure
23.6
12.0
12.0
+97.2%
Free cash flow
148
-108
161
Free cash flow margin
106.8%
-122.5%
95.4%
Cash from investing
-142
-241
-47.7
Cash from financing
11.3
258
66.4
-95.6%
Depreciation and amortisation
6.6
4.2
2.7
+57.1%
Share-based compensation
76.7
43.4
12.4
+76.7%
Diluted shares, weighted
104m
101m
99m
+3.0%
Shares outstanding at period end
104m
102m
96m
+1.9%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
409
462
245
-11.5%
Non-controlling interest
0.0
n/a
-0.6
Debt
0.0
0.0
0.0
Operating lease liabilities
23.3
20.0
n/a
+16.2%
Other liabilities
278
40.7
106
+583.4%
Total liabilities and equity
710
523
350
+35.9%
Fixed assets
48.7
30.9
23.2
+57.6%
Intangible assets
13.7
15.4
17.1
-11.1%
Investments
127
85.0
n/a
+49.1%
Securities held for sale or to maturity
n/a
n/a
81.1
Cash and equivalents
184
144
222
+28.5%
Receivables
10.3
0.8
0.7
+1,112.6%
Other assets
326
247
6.0
+32.2%
Total assets
710
523
350
+35.9%
10-K for the year ended 30 September 2021, filed 22 November 2021: the filing.